Upgrade to SI Premium - Free Trial

Jefferies: Oral Wegovy Outpacing Injectables; Lilly (LLY) Well-Positioned Ahead of April PDUFA

March 20, 2026 8:14 AM
Jefferies analyst Akash Tewari reiterated a Buy rating and $1,300.00 price target on Eli Lilly (NYSE: LLY)The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments